Browse the evidence

GLP-1 RA therapy is associated with significant reductions in procedural interventions (RR, 0.44; 95% CI, 0.30-0.63; P < .001).

GLP-1 RAs may reduce the need for surgical or other procedural interventions in IIH management.

Visceral obesity is correlated with cardiometabolic diseases and higher mortality.

Monitoring visceral fat levels can be crucial for assessing mortality risk.

Individuals with obesity are at greater risk for developing metabolic diseases such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and cardiovascular diseases.

Healthcare providers should monitor metabolic health in patients with obesity.

Semaglutide treatment led to larger reductions in glycated hemoglobin levels compared to the control group (−1.3% vs. −0.6%; P <0.001).

Semaglutide may improve glycemic control in patients post-ablation.

Durable LVAD patients treated with GLP-1 RA had a significant weight reduction from 116 kg to 110 kg (p-value < 0.001).

GLP-1 RA may be effective for weight management in LVAD patients.

Incretin-based anti-obesity medications are gaining interest for their potential role in preconception care.

Healthcare providers should consider the use of incretin-based medications in preconception counseling.

Ninety-day medical complications were significantly reduced in GLP-1 RA users across BMI categories ≥25.

Practitioners may consider GLP-1 RA use to reduce post-operative complications in obese patients.

Two-year surgical complications were lower among GLP-1 RA users in BMI 35 to 39.9 and ≥40 groups.

GLP-1 RA may be beneficial for reducing long-term surgical complications in higher BMI patients.

GLP-1 RA use was associated with significantly reduced risk of revision at 10 years in the 25.0 to 29.9 BMI group.

Consideration of GLP-1 RA may improve long-term surgical outcomes in patients with lower BMI.

Semaglutide improved lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels.

Semaglutide may be beneficial for improving lipid profiles in patients with T2DM.

Lifestyle interventions demonstrate favorable effects on lipid metabolism independent of weight loss.

Encourage patients to adopt lifestyle changes for lipid management, even if weight loss is not achieved.

GLP-1 receptor agonists (GLP-1 RAs) have been presumed to positively influence erectile function.

GLP-1 RAs may be considered in the management of erectile function in diabetic patients.

The composition of weight loss tracked as predicted a priori from weight change and baseline body composition.

Practitioners can use baseline body composition to predict changes during weight loss interventions.

Genetic proxies for body weight reduction via GIP receptor targeting reduces the risk of MACE and heart failure, mediated partly through lower BMI and partly through lower HbA1c.

Understanding GIP receptor pathways can inform strategies for reducing cardiovascular risks.

Lifestyle intervention alone is typically associated with approximately 2%-5% weight loss at 1 year of follow-up.

Practitioners should set realistic weight loss expectations for patients relying solely on lifestyle changes.

Bariatric surgery has the greatest degree of expected weight loss, at around 20%-30% at 1 year.

Bariatric surgery may be the most effective option for patients needing significant weight loss.

Significant reductions in diastolic BP (-1.5 mm Hg) and systolic BP (-1.1 mm Hg) were observed.

Semaglutide may help lower blood pressure in adults.

Metabolic adaptation hinders the efficacy of obesity management strategies.

Understanding metabolic adaptation can help practitioners develop more effective obesity management strategies.

Bariatric surgery is a highly effective intervention to induce weight loss with durability over 10 or more years.

Bariatric surgery can be considered a long-term solution for significant weight loss.

There is a distinct correlation between type 2 diabetes status and the likelihood of heart failure.

Recognizing this correlation can guide healthcare providers in monitoring and managing heart health in diabetic patients.

Weight gain within the first 6 months was associated with increased risk of HbA1c >7.5% and subsequent cardiovascular disease (CVD) with a hazard ratio (HR) of 1.03.

Clinicians should monitor weight changes in T2D patients as it may impact glycemic control and cardiovascular health.

Weight gain at 1 year was associated with increased risk of HbA1c >7.5% (HR 1.05) and kidney disease (HR 1.03).

Weight management is crucial for T2D patients to prevent worsening glycemic control and kidney disease.

Weight gain was associated with lower diabetes treatment satisfaction.

Healthcare providers should address weight management to improve patient satisfaction with diabetes treatment.

Soy isoflavones may be helpful in treating conditions such as insulin resistance, inflammation, cardiovascular disease, and intestinal dysbiosis.

Soy isoflavones could be considered as a potential treatment option for various metabolic conditions associated with PCOS.